A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. (Q48835641)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 2003

Language	Label	Description	Also known as
English	A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.	scientific article published in February 2003

Statements

scholarly article

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. (English)

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

author name string

Peter Y K Yong

1

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

Sandra Brett

2

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

David T Baird

3

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

K J Thong

4

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

language of work or name

0 references

publication date

1 February 2003

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

Fertility and Sterility

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

79

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

2

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

308-315

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

A model for follicular selection and ovulation: lessons from superovulation

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon).

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Ovarian tumors in a cohort of infertile women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Structure-function relationship of recombinant follicle stimulating hormone (Puregon).

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Control of preovulatory follicular estrogen biosynthesis in the human ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Follicular development during the luteal phase of the human menstrual cycle.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Superovulation with a high gonadotropin dose for in vitro fertilization: is it effective?

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

A model conforming the decline in follicle numbers to the age of menopause in women.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Use of the antral follicle count to predict the outcome of assisted reproductive technologies.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904583-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0015-0282(02)04583-1

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/12568839

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48835641&oldid=1387122745"